The estimated Net Worth of Margaret Dalesandro is at least $62.3 Thousand dollars as of 26 May 2022. Margaret Dalesandro owns over 35,000 units of OncoSec Medical Inc stock worth over $9,800 and over the last 6 years he sold ONCS stock worth over $0. In addition, he makes $52,472 as Independent Chairman of the Board at OncoSec Medical Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Margaret Dalesandro ONCS stock SEC Form 4 insiders trading
Margaret has made over 2 trades of the OncoSec Medical Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 35,000 units of ONCS stock worth $21,000 on 26 May 2022.
The largest trade he's ever made was buying 35,000 units of OncoSec Medical Inc stock on 26 May 2022 worth over $21,000. On average, Margaret trades about 4,583 units every 23 days since 2019. As of 26 May 2022 he still owns at least 35,000 units of OncoSec Medical Inc stock.
You can see the complete history of Margaret Dalesandro stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Margaret Dalesandro biography
Dr. Margaret Dalesandro Ph.D. serves as Independent Chairman of the Board of the Company. Dr. Dalesandro previously served as Business Director of Corning Integrative Pharmacology (CIP). Prior to CIP, Dr. Dalesandro held a senior executive leadership role at ImClone Systems and was in charge of the project management for clinical development of ERBITUX ® (cetuximab) and made significant contributions to the$6.5 billion-dollarsale of the ImClone to Eli Lilly in 2008. Previous to ImClone, Dr. Dalesandro served as an Executive Director at GlaxoSmithKline, managing cardiovascular, urology, and oncology drug product commercialization. Before GSK, Dr. Dalesandro was a Senior Consultant at Cambridge Pharma Consultancy. Earlier in her career, she was Director of Immunobiology and Diagnostic Research at Centocor and Assistant Director of Immunobiology. Dr. Dalesandro holds a Ph.D. and M.A. in Biochemistry fromBryn Mawr Collegeand an A.B. in Biology and Chemistry fromRosemont College, where she graduated summa cum laude. Currently, Dr. Dalesandro is the President of Brecon Pharma Consulting, a full-service pharmaceutical and biotech consultancy focused on identifying and obtaining critical information early in product development.
What is the salary of Margaret Dalesandro?
As the Independent Chairman of the Board of OncoSec Medical Inc, the total compensation of Margaret Dalesandro at OncoSec Medical Inc is $52,472. There are 2 executives at OncoSec Medical Inc getting paid more, with Daniel O'Connor having the highest compensation of $1,176,720.
How old is Margaret Dalesandro?
Margaret Dalesandro is 73, he's been the Independent Chairman of the Board of OncoSec Medical Inc since 2020. There are no older and 11 younger executives at OncoSec Medical Inc.
What's Margaret Dalesandro's mailing address?
Margaret's mailing address filed with the SEC is 24, North Main Street, Pennington, Mercer County, New Jersey, 08534, United States of America.
Insiders trading at OncoSec Medical Inc
Over the last 12 years, insiders at OncoSec Medical Inc have traded over $1,474,366 worth of OncoSec Medical Inc stock and bought 9,275,650 units worth $39,853,210 . The most active insiders traders include Grand Pharmaceutical & Heal..., Holdings, Inc. Alpha, and Robert Ward. On average, OncoSec Medical Inc executives and independent directors trade stock every 62 days with the average trade being worth of $51,563. The most recent stock trade was executed by Robert J Del Aversano on 9 February 2023, trading 40 units of ONCS stock currently worth $55.
What does OncoSec Medical Inc do?
oncosec is a san diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients. our technology, immunopulse™, is designed to enhance the local delivery and uptake of dna-based immune-targeting agents, such as il-12. clinical trials of immunopulse™ il-12 demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. our lead program, immunopulse™ il-12, is currently in phase ii development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. to date, study results have laid the groundwork for the expansion into new dna-encoded therapeutic candidates and tumor indications. we ar
What does OncoSec Medical Inc's logo look like?
Complete history of Margaret Dalesandro stock trades at OncoSec Medical Inc, Seelos Therapeutics, and Ambrx Biopharma
OncoSec Medical Inc executives and stock owners
OncoSec Medical Inc executives and other stock owners filed with the SEC include:
-
Daniel O'Connor,
President, Chief Executive Officer, Director -
Robert J. DelAversano CPA,
VP of Fin. and Principal Accounting Officer & Controller -
Margaret Dalesandro,
Independent Chairman of the Board -
Herbert Lyerly,
Independent Director -
Chao Zhou,
Director -
Yuhang Zhao,
Director -
Kevin Smith,
Director -
Robert DelAversano,
Principal Accounting Officer, Controller -
Robert Ward,
Independent Director -
James DeMesa,
Independent Director -
Joon Kim,
Director -
Dr. Mai Hope Le M.D.,
Consultant -
Dr. Sandra Aung Ph.D.,
Sr. VP & Chief Clinical Devel. Officer -
Tu Diep M.Sc.,
Sr. VP & Head of Operations -
Dr. Kim Jaffe,
Assistant VP of Bus. Devel. & Operations -
Robert Hamilton Pierce,
Chief Medical Officer -
Sheela Mohan Peterson,
Chief Legal Officer -
Sharron E Gargosky,
Chief Clinical & Reg. Officer -
Anthony E Iii Maida,
Director -
Mai Hope Le,
Chief Medical Officer -
Richard B Slansky,
Chief Financial Officer -
Avtar S Dhillon,
Director -
Punit Dhillon,
President and CEO -
Annalisa Jenkins,
Director -
Gregory T. Mayes,,
Director -
Sara Bonstein,
CFO/COO -
Spahr Stephany Foster,
Director -
Veronica Vallejo,
Chief Financial Officer -
Grand Pharmaceutical & Heal...,
-
Kellie Malloy Foerter,
Chief Operating Officer -
Holdings, Inc. Alpha,
Director -
Brian A Leuthner,
Interim CEO -
Robert H. Arch,
President and CEO